Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

PRESCIENT THERAPEUTICS LIMITED

INVESTOR PRESENTATION - PRESCIENT THERAPEUTICS LIMITED

ASX:PTX

PRESCIENT THERAPEUTICS LIMITED

Health Care

Prescient Therapeutics is a clinical stage oncology company developing novel drugs that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

Market Cap

41.00m

Price at Close

$0.064

4w avg. Volume

4.84m

4w avg. Turnover

$326.42k

Announcements
announcementt+2 movementdate
  • Response to ASX Query

    ASX Query · Market sensitive

  • 0.00%

    16 Sep 2020

0.00%

16 Sep 2020
  • Ceasing to be a substantial holder

    Shareholder Details

  • -7.58%

    03 Sep 2020

-7.58%

03 Sep 2020
  • Change in Substantial Holding from AEF

    Shareholder Details

  • -7.58%

    02 Sep 2020

-7.58%

02 Sep 2020
  • Section 708A Cleansing Notice and Appendix 2A

    Issued Capital

  • -9.59%

    31 Aug 2020

-9.59%

31 Aug 2020
  • Change of Director's Interest Notice

    Shareholder Details

  • -9.59%

    30 Aug 2020

-9.59%

30 Aug 2020
  • Becoming a Substantial Holder from AEF

    Shareholder Details

  • 0.00%

    26 Aug 2020

0.00%

26 Aug 2020
  • Ceasing to be a substantial holder from AEF

    Shareholder Details

  • 0.00%

    26 Aug 2020

0.00%

26 Aug 2020
  • Proposed issue of Securities - PTX

    Issued Capital

  • -15.58%

    25 Aug 2020

-15.58%

25 Aug 2020
  • PTX Raises $7 million via Strongly Supported Placement

    Issued Capital · Market sensitive

  • -15.58%

    25 Aug 2020

-15.58%

25 Aug 2020
  • Appendix 4G and Corporate Governance Statement

    Periodic Reports

  • -15.58%

    25 Aug 2020

-15.58%

25 Aug 2020
Market Data

Current Price

$0.064

52WK HIGH

$0.15

52WK LOW

$0.022

1YR RETURN

+3.23%

1YR RETURN VS. SECTOR

-30.31%

90 DAY RETURN

+18.52%

ASX RANK

1,117

/2,018

SECTOR RANK

30

/47

SHARES OUTSTANDING

640.55m
ASX:PTX

PRESCIENT THERAPEUTICS LIMITED

Health Care

Prescient Therapeutics is a clinical stage oncology company developing novel drugs that show great promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

Market Cap

41.00m

Price at Close

$0.064

4w avg. Volume

4.84m

4w avg. Turnover

$326.42k

ASX:PTX is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.